EUVIMEDEUVIMED entdecken
Übersichtsarbeit

HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started

Milena Ivanova iD, Velizar Shivarov iD

International Journal of Immunogenetics · 2021-04 · 48 (2) · 193-200

DOI: 10.1111/iji.12517 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Immunogenetics, online erschienen am 28.10.2020. Verfasst von Milena Ivanova und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, University Hospital Alexandrovska, Medical University Sofia, Sofia, Bulgaria. Hauptthemen laut MEDLINE: Immunotherapy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: NSF (Bulgaria).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The implementation of the immune checkpoint blockade as a therapeutic option in contemporary oncology is one of the significant immunological achievements in the last century. Constantly accumulating evidence suggests that the response to immune checkpoint inhibitors (ICIs) is not universal. Therefore, it is critical to identify determinants for response, resistance and adverse effects of immune checkpoint therapy that could be developed as prognostic and predictive markers. Recent large scale analyses of cancer genome data revealed the key role of HLA class I and class II molecules in cancer immunoediting, and it appears that HLA diversity can predict response to ICIs. In the present review, we summarize the emerging data on the role of HLA germline variations as a marker for response to ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyAntigen PresentationAntigens, NeoplasmAntineoplastic Agents, ImmunologicalB7-H1 AntigenDrug Resistance, NeoplasmGenes, MHC Class IGenes, MHC Class IIGenetic VariationGenotypeGerm-Line MutationHLA AntigensHumansImmune Checkpoint InhibitorsNeoplasmsPrognosisProgrammed Cell Death 1 ReceptorSelf ToleranceT-Lymphocytes, CytotoxicTumor Escape

Stichwörter der Autor:innen

HLAcancerimmune checkpoint inhibitorsresponse

Substanzen

Antigens, NeoplasmAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humanHLA AntigensImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Clinical Immunology, University Hospital Alexandrovska, Medical University Sofia, Sofia, Bulgaria.
  • Department of Genetics, St. Kliment Ohridski University, Sofia, Bulgaria.

ORCID-Profile: Milena Ivanova, Velizar Shivarov

Förderung

  • NSF (Bulgaria)

Zitieren

APA

Ivanova, M., & Shivarov, V. (2021). HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started. International Journal of Immunogenetics, 48(2), 193-200. https://doi.org/10.1111/iji.12517

Vancouver

Ivanova M, Shivarov V. HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started. International Journal of Immunogenetics. 2021;48(2):193-200. doi:10.1111/iji.12517

BibTeX
@article{Ivanova2021,
  author = {Ivanova, Milena and Shivarov, Velizar},
  title = {HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started},
  journal = {International Journal of Immunogenetics},
  year = {2021},
  volume = {48},
  number = {2},
  pages = {193--200},
  doi = {10.1111/iji.12517}
}
Kostenlos starten →